TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9773717
Drug: Implantable Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implantable Insulin Pump (IIP) therapy
Study: 9773717
Drug: Multiple-Dose Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-Dose Insulin (MDI) therapy
Study: 8148225
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (100 mg elemental iron) with norfloxacin (400 mg)
Study: 8148225
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (100 mg elemental iron) with ciprofloxacin (500 mg)
Study: 8148225
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (100 mg elemental iron) with ofloxacin (400 mg)
Study: 3167505
Drug: Peritendonous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritendonous injection of 40 mgs of methyl prednisolone acetate (Depo Medrone)
Study: 3167505
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.25% marcaine alone
Study: 31874736
Drug: Goal Directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal Directed Fluid Therapy (GDFT) using non-invasive cardiac output monitoring for 12 hours
Study: 29292264
Drug: Control (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single anesthetic agent)
Study: 25877225
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² for level 1 and 1200 mg/m² for level 2 on day 1), Cisplatin (30 mg/m² fixed dose on day 1), S-1 (40-60 mg/day fixed dose twice a day for 7 days), every 2 weeks until progression
Study: 21552482
Drug: Guided internet
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet self-help treatment program (22 patients)
Study: 19940609
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day laropiprant
Study: 11513787
Drug: Combination gloves
Normalized name: GLOVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination gloves
Study: 9096447
Drug: rHuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO therapy for 6 months in group I (n = 20)
Study: 9096447
Drug: rHuEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO therapy and iron supplement in group II (n = 20)
Study: 8502627
Drug: Single 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 800 mg dose of pefloxacin
Study: 8502627
Drug: 10 days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days' course of norfloxacin 400 mg bid
Study: 3573825
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion (2 mg/kg over 5 minutes)
Study: 26971081
Drug: Sertraline 200
Normalized name: sertraline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 200 mg/day
Study: 27659276
Drug: 5% benzocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% benzocaine gel
Study: 24100112
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication therapy (20 mg omeprazole, 1 g amoxicillin, and 500 mg clarithromycin twice daily for 1 week)
Study: 10872661
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication therapy
Study: 22662132
Drug: Topical insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical insulin cream
Study: 20137365
Drug: 30‐minute formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐minute formula electro‐acupuncture treatment
Study: 15583944
Drug: Potentiometric immunosensor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentiometric immunosensor for adrenal cortical hormones (ACH)
Study: 9521952
Drug: Ciprofloxacin oral
Normalized name: ciprofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin oral suspension (10 mg/kg body weight, three times daily)
Study: 7570860
Drug: Preventive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive therapy for tuberculosis
Study: 22633265
Drug: GnRH antagonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonists
Study: 27871928
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg daily for 6 months
Study: 18398457
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin daily
Study: 25769003
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin daily
Study: 25769003
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose atorvastatin
Study: 23826798
Drug: Multidimensional Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidimensional Treatment Foster Care for Preschoolers
Study: 17083766
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and prednisolone
Study: 15305885
Drug: Intralipid with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid with heparin
Study: 10708327
Drug: Community-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based drug prevention, education, and treatment projects providing case management and referral to services or day treatment
Study: 8507346
Drug: MDE (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDE (140 mg)
Study: 27500639
Drug: DNA prime-recombinant
Normalized name: somatropin (recombinant DNA origin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine
Study: 24377454
Drug: Pistachio nuts
Normalized name: Pistachio nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pistachio nuts (20% energy daily)
Study: 22592096
Drug: 0.5-1.0 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-1.0 µg calcitriol and 1200 IU (30 µg) cholecalciferol
Study: 22592096
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in parathyroid hormone
Study: 18678155
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at Shuigou (GV 26) plus western medicine
Study: 18630533
Drug: Simple western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple western medicine
Study: 10367592
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg, n = 11)
Study: 10367592
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (n = 11)
Study: 1677361
Drug: Clonidine (0.300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.300 mg, orally) and Pyridostigmine (120 mg, orally)
Study: 1677361
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg, im)
Study: 1677361
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg, im) and Clonidine (0.300 mg, orally)
Study: 1677361
Drug: Yohimbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (30 mg, orally)
Study: 6342357
Drug: Coingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coingestion of 50 g fat (butter) with 50 g carbohydrate (potato)
Study: 6342357
Drug: Coingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coingestion of 50 g fat (butter) with 50 g protein (low fat veal)
Study: 31237182
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) after four treatments
Study: 29987144
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of Naphthoquine-Azithromycin (NQAZ)
Study: 29987144
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of Naphthoquine-Azithromycin (NQAZ)
Study: 16618270
Drug: Olmesartan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (10 to 40 mg)
Study: 17210069
Drug: ATP infusions
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP infusions with usual palliative care and dietetic advice
Study: 9583926
Drug: Levodopa and
Normalized name: levodopa and decarboxylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa and a dopa decarboxylase inhibitor in combination with selegiline (arm 2)
Study: 9583926
Drug: Levodopa and
Normalized name: levodopa and decarboxylase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa and a dopa carboxylase inhibitor (arm 1)
Study: 2696670
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravitreal 5-FU
Study: 22440491
Drug: Tirofiban 25
Normalized name: tirofiban 250 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban 25 μg/kg bolus
Study: 22440491
Drug: Tirofiban bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban bolus with post-bolus 2-h infusion
Study: 21053455
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and beta2 agonists for eight weeks (Group A)
Study: 21053455
Drug: Oral beta2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beta2 agonists only for eight weeks (Group B)
Study: 7843758
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 mg)
Study: 10421037
Drug: Cefazolin-oxacillin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin-oxacillin combination (group C, 300 patients)
Study: 2205964
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg on the first day, then 50 mg daily)
Study: 6444678
Drug: Topical program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical program of tretinoin, benzoyl peroxide, and water avoidance
Study: 6444678
Drug: Systemic tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic tetracycline therapy with abradant cleansers
Study: 6444678
Drug: Systemic tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic tetracycline therapy with topically applied tretinoin
Study: 6444678
Drug: Topical program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical program
Study: 31977842
Drug: Letrozole (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5.0 mg/d on days 3-5 of menstrual cycle for 5 days)
Study: 31977842
Drug: Human Menopausal
Normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human Menopausal Gonadotropin (75 U/d intramuscular injection starting from day 3 of menstrual cycle for 5 days)
Study: 23111014
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound dressing treatment (Prevena, KCI, Wiesbaden, Germany) with -125 mm Hg for 6 to 7 days
Study: 23111014
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound dressing treatment
Study: 19296295
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only antipsychotics
Study: 8943580
Drug: Cocaine treatment
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine treatment trial
Study: 1742266
Drug: 10% solution
Normalized name: Mucomyst 10% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% solution of povidine-iodine for pre-operative skin preparation
Study: 1742266
Drug: No skin
Normalized name: Aveeno Skin Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: No skin preparation (control group)
Study: 6128012
Drug: Org NC
Normalized name: ORG NC 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org NC 45 (0.1 mg kg‐1)
Study: 8904256
Drug: Pancuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium (0.1 mg kg‐1)
Study: 28493510
Drug: Rocuronium 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.45 mg.kg‐1 with neostigmine (50 μg.kg‐1 with glycopyrrolate 10 μg.kg‐1)
Study: 28493510
Drug: Rocuronium 0.90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.90 mg.kg‐1 with sugammadex (4 mg.kg‐1)
Study: 22451244
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 5 mg oxycodone hydrochloride
Study: 22451244
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of 5 mg oxycodone hydrochloride
Study: 22451244
Drug: Capsule of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule of 5 mg oxycodone hydrochloride
Study: 22451244
Drug: Controlled-release tablet
Normalized name: ALAmax CR Controlled-Release Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release tablet of 5 mg oxycodone hydrochloride
Study: 20965827
Drug: Pulsed magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsed magnetic field treatment (20-40 mT, 50 Hz, 20 min per time, 1 time per day for 14 days)
Study: 9872822
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (Foradil) 24 microgram, twice a day for 8 weeks
Study: 9872822
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 microgram, twice a day for 8 weeks
Study: 9872822
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo inhaled twice a day for 8 weeks
Study: 7720758
Drug: Captopril 12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5-50 mg per day (divided in 2-3 doses) p.o. in addition to 'conventional' therapy with digoxin and diuretics
Study: 7720758
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy only (control group)
Study: 1827043
Drug: Betaxolol, furosemide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol, furosemide, and minoxidil combination
Study: 30765298
Drug: Electronic reminders
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic reminders (weekly messages based on behavioral psychology principles)
Study: 29929537
Drug: Risperidone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (up to 4 mg orally)
Study: 27090728
Drug: Analgesic pharmacotherapy
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic pharmacotherapy
Study: 24108527
Drug: Galsulfase 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galsulfase 1.0 mg/kg/week
Study: 24108527
Drug: Galsulfase 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galsulfase 2.0 mg/kg/week
Study: 24108527
Drug: Galsulfase 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galsulfase 1.0 mg/kg/week and 2.0 mg/kg/week
Study: 19556526
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with overground gait training only (n=45)
Study: 21914118
Drug: Transforaminal (TF)
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal (TF) epidural steroid injection
Study: 17456677
Drug: Caudal (C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal (C) epidural steroid injection
Study: 8885803
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray (220 micrograms/day)
Study: 1333781
Drug: Celiprolol 200
Normalized name: celiprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 200 mg (C200)
Study: 1333781
Drug: Celiprolol 400
Normalized name: celiprolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 400 mg (C400)
Study: 1333781
Drug: Celiprolol 800
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 800 mg (C800)
Study: 6724256
Drug: chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chenodeoxycholic acid (1 g/day)
Study: 6724256
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid (1 g/day)
Study: 21576829
Drug: Non-ARB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ARB treatment
Study: 16080838
Drug: High-dose glucose-insulin-potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucose-insulin-potassium (GIK) infusion for 24 hours
Study: 9667263
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive preoperative chemotherapy regimen (two courses of cisplatin and doxorubicin in addition to high‐dose methotrexate and bleomycin, cyclophosphamide, and dactinomycin)
Study: 9667263
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (therapy based on the T10 protocol)
Study: 9667263
Drug: More intensive
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More intensive preoperative chemotherapy regimen
Study: 8138256
Drug: Interferon-alpha treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha treatment for 4 months
Study: 28270726
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (30 minutes daily for 2 weeks)
Study: 20137437
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of diprospan (compound betamethasone) 3 ml (B group)
Study: 20137437
Drug: Interventional injection
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventional injection of diprospan (compound betamethasone) 1 ml + songmeile (cervus & cucumis polypeptide injection) 2 ml (C group)
Study: 20137437
Drug: Intradiscal injection
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal injection of normal saline 3 ml (A group, control)
Study: 18075283
Drug: Acute insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute insulin infusion (euglycemic hyperinsulinemic clamp)
Study: 15007248
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy in locally advanced gastric cancer
Study: 12614251
Drug: Tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 2 mg twice daily plus simplified bladder training (BT)
Study: 10325795
Drug: Sucrose administered
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose administered into the mouth
Study: 10325795
Drug: Sucrose administered
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose administered intragastrically
Study: 7569002
Drug: Split course
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split course therapy
Study: 7569002
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily radiation therapy
Study: 14711910
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100 mg daily)
Study: 7015797
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg once daily, increased to 200 mg if needed)
Study: 7015797
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg once daily, increased to 200 mg if needed)
Study: 26716547
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol combined with topical timolol maleate (Experimental group A)
Study: 26716547
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol alone (Control group B)
Study: 24868014
Drug: 15% H(2)O(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% H(2)O(2) bleaching agent with TiO_N photocatalyzed with LED/laser light (HP15)
Study: 21738095
Drug: Physician education
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician education in combination with motivational counseling (MC)
Study: 17241304
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg b.i.d.), tetracycline (500 mg q.i.d.), and metronidazole (250 mg q.i.d.)
Study: 17241304
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.)
Study: 3802930
Drug: Bronchodilator pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator pretreatment
Study: 3802930
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose oral steroid therapy
Study: 24233256
Drug: Fiber-blend fortified
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-blend fortified enteral formula (FB, 15 g/L)
Study: 24521695
Drug: Nimotuzumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab (200 mg doses, first 6 doses weekly, then every 21 days for up to 1 year)